Roche bids for broad use of HPV test to screen for cervical cancer

Roche ($RHHBY) is aiming to make its human papillomavirus test a first-line diagnostic for cervical cancer, with a new FDA application for the Cobas HPV as a substitute for Pap tests. Currently the test is approved for use along with Pap testing. Report